Stock Taper 
Inventiva S.A. is a French clinical-stage biopharmaceutical company developing oral therapies for NASH, MPS, and other diseases, with lead candidates Lanifibranor and Odiparcil, and collaborations with AbbVie and Boehringer Ingelheim.
Lanifibranor, Inventiva's lead oral small molecule for MASH, is in Phase 3 trials, the only pan-PPAR agonist in development for this, with FDA Breakthrough Therapy and Fast Track designations.
In November 2025, Inventiva announced a public offering of American Depositary Shares (ADSs) which was initially planned for $125 million, then upsized to approximately $150 million, and finally, with the full exercise of the underwriters' option, raised gross proceeds of about $172.5 million. This successful and expanded capital raise was the most notable event of the year, demonstrating significant investor interest and providing the company with substantial funding to continue its pivotal Phase 3 clinical trial for its lead drug candidate, lanifibranor.
In a major strategic realignment, Inventiva S.A. announced its '2025 Pipeline Prioritization Plan' to cease all preclinical research activities and reduce its workforce by approximately 50%. This decision concentrates all of the company's resources on the clinical development of its lead drug candidate, lanifibranor, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Inventiva NASDAQ: IVA said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, or MASH.
Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report)'s share price gapped down before the market opened on Thursday. The stock had previously closed at $3.69, but opened at $3.38. Inventiva shares last traded at $3.7150, with a volume of 1,531,710 shares. Analyst Ratings Changes Several equities research analysts have recently commented on IVA shares.
Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report) shares gapped up prior to trading on Wednesday. The stock had previously closed at $3.29, but opened at $3.51. Inventiva shares last traded at $3.6650, with a volume of 400,933 shares traded. Wall Street Analyst Weigh In A number of research firms have commented on IVA.
Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report) has earned a consensus rating of "Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and three have given a strong buy recommendation to the
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
 AVTX | $13.15 | COMPARE |
 ENTA | $12.22 | COMPARE |
 OBIO | $5.81 | COMPARE |
 EPRX | $7.55 | COMPARE |
 NAUT | $1.77 | COMPARE |
 IVVD | $0.71 | COMPARE |
 RNAC | $6.73 | COMPARE |
 TNYA | $0.54 | COMPARE |
